RIFAXIMIN
Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
1 .- 22 . (canceled)
23 . A pharmaceutical composition comprising amorphous rifaximin, silicon dioxide, disodium edetate, hydroxypropyl methyl cellulose, microcrystalline cellulose, sodium starch glycolate, and glycerol palmitostearate.
24 . The pharmaceutical composition of claim 23 , wherein the amorphous rifaximin is characterized by the XRPD pattern shown in FIG. 1 .
25 . The pharmaceutical composition of claim 23 , wherein the pharmaceutical composition is in tablet form.
26 . A method of treating a bowel related disorder in a patient in need thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 23 to the patient.
27 . The method of claim 26 , wherein the bowel related disorder is selected from the group consisting of irritable bowel syndrome, traveler's diarrhea, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, and colitis.